Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Erasca Inc. (ERAS)

NASDAQ: ERAS · Pharmaceutical Preparations · San Diego, CA

Our rating: Neutral

Call changed from Cautious to Neutral at $15.66, low conviction, November 13, 2026.

Breaks if: The Neutral call turns Cautious if the stock falls more than 35% from today's $15.66 within roughly six months — a decline of that magnitude would almost certainly reflect a clinical setback or financing stress not yet captured in the figures — or if the next 10-Q discloses a cash balance below $400 million, implying fewer than five quarters of runway at the current burn rate. It turns Positive if Erasca reports a statistically significant positive pivotal readout or receives FDA acceptance of a New Drug Application for a lead candidate before the end of the second quarter of 2027.

Key figures

Market value$4.8B
Revenue, last 12 monthsn/a
Net income, last 12 months−$308M
Free cash flow, last 12 months−$109M
Price to earningsn/a
Free cash flow yield−2.3%
Dividend yield0.0%
Operating marginn/a
Return on equity−48.7%
Beta to the S&P 5001.43
Volatility, annualized90.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-0.15−$33M
June 30, 2026n/an/a$-0.14−$27M
March 31, 2026n/an/a$-0.60−$27M
December 31, 2025n/an/a$-0.10−$22M
September 30, 2025n/an/a$-0.11−$22M
June 30, 2025n/an/a$-0.12−$21M
March 31, 2025n/an/a$-0.11−$32M
December 31, 2024n/an/a$-0.09−$25M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

37 ledger entries and 9 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.